0216/26SCR018-12/R4RGB
Media Highlights
From the 2025 ASH Annual Meeting
7
Media Outlet Article / Coverage
HealthTree Mosunetuzumab: A Potential Option for Frail #DLBCL
Patients | Jeff Sharman, MD | #ASH2025
MedPage Today Mosunetuzumab in DLBCL Shows Promise as Frontline
Option for Elderly Patients
OncLive ASH 2025 Updates Signal Expanding Applications for
Immunotherapy and T-Cell Therapies Across Leukemia and
Lymphoma
Oncology Learning Network Subcutaneous Mosunetuzumab Shows Efficacy and Safety
Among Elderly, Chemotherapy-Ineligible Patients With
DLBCL: MorningSun Trial
Oncology Learning Network Mosunetuzumab Demonstrates Strong Efficacy for Elderly
Patients With Diffuse Large B-Cell Lymphoma
Oncology News Central Elderly or Unfit Patients With DLBCL May Benefit From
Subcutaneous Mosunetuzumab
VJHemOnc ASH 2025 | Fixed-duration SC Mosunetuzumab in Older
Patients With Previously Untreated DLBCL: MorningSun Trial
Jeff Sharman, MD
SCRI at Willamette Valley Cancer Institute & Research Center I The US Oncology Network
